11 November 2024
Hemogenyx
Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Institutional Investment of £600,000
Hemogenyx
Pharmaceuticals Secures £0.6m for Phase I Clinical
Trials
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the biopharmaceutical group focused on developing new
therapies for blood diseases, is pleased to announce that it was
approached by an institutional investor and that this investor has
subscribed £600,000, for the issue of 60,000,000 new Ordinary
Shares at 1p per share.
The net proceeds of this
subscription will be dedicated to the imminent commencement of
the Phase I clinical trials for the Company's Chimeric
Antigen Receptor T-cell therapy ("HEMO-CAR-T" or "HG-CT-1"), aimed
at treating acute myeloid leukemia ("AML").
The Company will keep the Market
informed of future developments as trials commence and
develop.
An application is being made to the
Main Market of the London Stock Exchange Main Market, and admission
of the Subscription Shares to trading is expected on or around 15
November 2024 ("Admission"). The Subscription Shares will rank
pari passu with the
Company's existing Ordinary Shares.
Dr
Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented: "We are greatly
encouraged by the confidence shown by our new institutional
investor and are grateful for their support in advancing our
mission to bring innovative treatments to patients with acute
myeloid leukemia. This investment enables us to take a significant
step forward with our HEMO-CAR-T program, moving into clinical
trials and bringing us closer to providing a new therapeutic option
for patients facing this aggressive disease."
Total
Voting Rights
For the
purpose of the Disclosure Guidance and Transparency Rules,
following Admission the enlarged issued share capital of the
Company will comprise 1,401,815,988 ordinary shares. The Company
does not hold any shares in treasury. The above figure may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.
Market
Abuse Regulation (MAR) Disclosure
Certain
information contained in this announcement would have been inside
information for the purposes of Article 7
of Regulation No 596/2014 (as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018) until the
release of this announcement. The person responsible for arranging
for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder.
Enquiries:
|
Hemogenyx Pharmaceuticals
plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
SP Angel Corporate Finance
LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
Peterhouse Capital
Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located
in New York City at its
state-of-the-art research facility.
The Company is a clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is
developing several distinct and complementary product candidates,
as well as platform technologies that it uses as engines for novel
product development.